Welcome to our dedicated page for Nexgel Wt Exp 120126 SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating NexGel’s R&D spending on electron-beam cross-linked hydrogels or tracking when executives buy warrants can take hours. The company’s filings are packed with technical terms about transdermal delivery science, FDA clearances, and contract-manufacturing revenue splits—details investors can’t afford to miss. If you have ever typed “NexGel SEC filings explained simply” or “how do I read NexGel’s annual report 10-K?” this page is built for you.
Stock Titan’s AI quickly translates dense disclosures into plain language. Need the NexGel quarterly earnings report 10-Q filing summarized before the market opens? Our engine highlights wound-care segment margins, cash burn, and backlog in seconds. Want alerts on NexGel insider trading Form 4 transactions? We stream NexGel Form 4 insider transactions real-time, flagging option exercises tied to milestone trials. From NexGel executive stock transactions Form 4 to an NexGel 8-K material events explained feed, every document lands here as soon as EDGAR posts it—complete with AI-powered summaries, keyword search, and side-by-side comparisons.
Investors use these insights to:
- monitor FDA-driven catalysts announced in 8-Ks
- compare hydrogel manufacturing costs across quarters
- review the NexGel proxy statement executive compensation for alignment with shareholder returns
- dive into an NexGel annual report 10-K simplified view that links R&D intensity to future growth
- follow NexGel earnings report filing analysis for margin trends
Adam R. Levy, Chief Executive Officer and a director of NexGel, Inc. (NXGL), reported a sale of 4,000 shares of common stock on 08/28/2025 at a weighted average price of $2.4741 per share. The filing states the sale was made for tax planning purposes. After the transaction, Mr. Levy beneficially owned 358,284 shares. The shares sold were originally acquired from the issuer on October 15, 2019. The report commits to provide specific per-price share counts if requested by the SEC, the issuer, or a security holder.
Form 144 notice for NexGel, Inc. (NXGLW) reports a proposed sale of 4,000 common shares through Charles Schwab with an aggregate market value of $9,800, scheduled approximately for 08/28/2025. The filing states the company has 8,067,580 shares outstanding, and the shares to be sold were acquired on 10/15/2019 via founder shares, a PIPE, ESOP and open market purchases.
The filer also discloses recent sales by the same person totaling 8,000 shares across five transactions from 05/30/2025 to 06/11/2025 with gross proceeds ranging from $2,218 to $4,779. The notice includes the required representation that the seller has no undisclosed material adverse information and a signature/attestation section. Several standard filer fields (CIK, contact details) are not populated in the provided text.
NexGel reported consolidated revenue of $2.884 million for the quarter ended June 30, 2025, up from $1.440 million a year earlier, and $5.690 million for the six months versus $2.706 million in 2024. Growth was driven largely by its consumer branded products, which produced $1.884 million in the quarter (vs. $968 thousand) and $3.666 million for six months (vs. $1.585 million).
Despite revenue gains, NexGel remains unprofitable: net loss attributable to NexGel stockholders was $1.377 million for the six months and the company used $807 thousand in operating cash over the period. Cash on hand was $725 thousand at June 30, 2025 and working capital was about $1.8 million, which the company says raises substantial doubt about its ability to continue as a going concern. Management is pursuing expanded sales channels, product development and possible financing to address liquidity needs.
NexGel, Inc. furnished a press release reporting the Companys results for the quarter ended June 30, 2025, attached as Exhibit 99.1, and disclosed a new investor presentation attached as Exhibit 99.2.
The filing states these materials are being furnished (not "filed") for purposes of the Exchange Act and therefore are not automatically incorporated by reference into other securities filings. The cover information lists the Companys common stock and warrants trading on The Nasdaq Capital Market under the symbols NXGL and NXGLW, and indicates the Company is an emerging growth company.
FAQ
What is the current stock price of Nexgel Wt Exp 120126 (NXGLW)?
